Intravenous administration of tramadol
AssigneeRevogenex Ireland Ltd
InventorLucy Lu
Life of this patent
Estimating the term…
Abstract
A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol about 25 mg and the second (and optionally) third doses are intravenously administered at intervals of about 2 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 hours, until the patient no longer requires treatment with tramadol.
Claims20
A method of administering tramadol for treating acute pain in human patients via an intravenous dosing regimen comprising intravenously administering a first dose of tramadol to human patients in an amount of about 25 mg;
- and thereafter intravenously administering additional doses of tramadol to the human patients in an amount of about 25 mg at dosage intervals of about 4 hours, except that a second dose is intravenously administered as a loading dose at a shortened interval as compared to the dosage interval of about 4 hours,
- until the patients no longer requires treatment with intravenous tramadol, wherein the tramadol is tramadol base or a pharmaceutically acceptable salt of tramadol.
A method of administering tramadol for treating acute pain in human patients via an intravenous dosing regimen comprising intravenously administering a first dose of tramadol to human patients in an amount of about 25 mg;
- and thereafter intravenously administering additional doses of tramadol to the human patients in an amount of about 25 mg at dosage intervals of about 4 hours, except that a second dose is intravenously administered as a loading dose at a shortened interval as compared to the dosage interval of about 4 hours,
- until the patients no longer require treatment with intravenous tramadol, wherein the tramadol is tramadol base or a pharmaceutically acceptable salt of tramadol and a reduction in at least one side-effect associated with tramadol therapy selected from the group consisting of nausea, vomiting, and seizure is achieved.
Dependencies are inferred from the claim text.